Educational resources

Celltrion supplement cover

Switching from intravenous to subcutaneous infliximab biosimilar (Remsima®) in adult patients with inflammatory bowel disease: experience at an NHS trust

Commissioned by Celltrion Healthcare UK Ltd

This supplement has been commissioned and funded by Celltrion Healthcare UK Ltd and developed in partnership with Guidelines in Practice.
View prescribing information
CTHC-UK-219D (1) October 2020